Navigation Links
Study: Harmless virus kills some cancers

Six days is all it takes for a common, non-disease-causing virus to kill cervical, breast, prostate and squamous cell cancer cells in laboratory cultures, according to Penn State College of Medicine researchers.

"Our results suggest that adeno-associated virus type 2 (AAV2), which infects the majority of the population but has no known ill effects, kills multiple types of cancer cells yet has no effect on healthy cells," said Craig Meyers, Ph.D., professor of microbiology and immunology, Penn State College of Medicine, Penn State Milton S. Hershey Medical Center. "We believe that AAV2 recognizes that the cancer cells are abnormal and destroys them. This suggests that AAV2 has great potential to be developed as an anti-cancer agent."

The study was presented June 20, 2005, at the 24th annual meeting of the American Society for Virology held June 18-22 at Penn State, University Park campus.

Although the reason why remains unclear, population-based studies have shown that people who carry AAV2 tend not to develop human papillomavirus- (HPV-) associated cervical cancer. In general, AAV2 requires association with a helper virus in order to replicate. When it finds a helper virus, such as HPV, AAV2 disrupts the life cycle of the host and induces apoptosis, a type of cell death.

"Even without co-mingling with another virus, AAV2 seems to be able to infect and express itself in other types of cancer cells also disrupting their ability to survive and inducing cell death," Meyers said. "Although we suspect it is, more studies are needed to determine if the mechanism through which AAV2 destroys cancer cells is the same."

Scientists often refer to cancer cells as deregulated, meaning they are no longer acting or communicating like normal, healthy cells. It appears that AAV2 is able to recognize cells that have undergone deregulation, infect them, express its own genes, which disrupt the host cell's life cycle and kill it.

Scientists have suspected that AAV2 has cancer-suppressing properties. In previous studies, Meyers and his team found that one of the ways AAV2 suppresses cancer is by inhibiting the normal process of DNA duplication of human papillomavirus (HPV). HPV is known to lead to cervical cancer. A second way AAV2 suppresses cancer is linked to its ability to slow cell-cycle progression by decreasing cancer cell proliferation rates and causing growth arrest.

In this study, the team first used HPV infected epithelial cells and normal human epithelial cells, which are natural hosts for both AAV2 and HPV. In cultures infected with both AAV2 and HPV, the team found that after six days, all HPV infected cells had died. Meyers then used the same approach in four types of cancer ?cervical, breast, prostate and squamous cell - all epithelial cell cancers. Epithelial cells are those that cover or line all of the internal and external parts of the body. No matter the type of epithelial cancer cells, when treated with AAV2, all cancer cells were dead in six days. Though previous have investigated the cancer-targeting potential of AAV2, none allowed the AAV2 to remain in culture long enough to see the effect that Meyers and his team observed.

"One of the most compelling findings is that AAV2 appears to have no pathologic effects on healthy cells," Meyers said. "So many cancer therapies are as poisonous to healthy cells as they are to cancer cells. A therapy that is able to distinguish between healthy and cancer cells could be less difficult to endure for those with cancer."

Though similar in design and effectiveness to some gene therapies, Meyers and his team did not modify the AAV2, but left it in its natural form. Therefore, it would not be classified as a gene therapy.

Future studies will investigate the precise mechanisms through which AAV2 causes cancer cell death, and how the virus might be enhanced to more aggressively target and kill cancers.

A prov isional patent application for this work was recently submitted.


'"/>

Source:Penn State


Related biology news :

1. Study: Soap And Water Work Best In Ridding Hands Of Disease Viruses
2. Study: homemade gene expression technology unreliable
3. Study: Well-known protein helps stem cells become secretory cells
4. Study: Predatory dinosaurs had bird-like pulmonary system
5. Study: Plants use dual defense system to fight pathogens
6. Study: Competition for sex is a jungle out there
7. Study: Paramedics save more lives when they dont follow the rules
8. Study: Living coral reefs provide better protection from tsunami waves
9. Harmless virus may hold key to more effective HIV drug discovery
10. Association of herpesvirus with lung disorder questioned
11. Topical treatment shown to inhibit HIV and herpes simplex virus infection
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/22/2020)... ... July 21, 2020 , ... ... and innovation in technology and compliance, announces a new solution to manage regulated ... ensure every layer of their technology stack complies with FDA and global regulations. ...
(Date:7/18/2020)... ... July 17, 2020 , ... Commercial launch readiness is a ... to discover a COVID cure or vaccine, the global economic downturn will only increase ... is not going away and capturing full value from every product launch is critical. ...
(Date:7/10/2020)... CHICAGO (PRWEB) , ... July 09, 2020 , ... Today ... Umami Advantage, which will share insight on the “fifth taste” phenomenon that is revolutionizing ... snacks. The Umami Advantage will be live on Monday, July 13, 2020 at11:00 AM ...
Breaking Biology News(10 mins):
(Date:8/7/2020)... ... 06, 2020 , ... VGXI, a highly regarded CDMO supporting ... purchase of greenfield for a new, expanded manufacturing facility. The site is located ... the initial acquisition, with an option to purchase an additional 21 acres for ...
(Date:7/31/2020)... ... , ... R3 Stem Cell International is now offering patients the opportunity to ... total, patients may choose which extremities they would like treated. , Several studies have ... 2016). At R3 International, umbilical cord tissue is obtained from a lab with a ...
(Date:7/31/2020)... ... July 29, 2020 , ... Anomet Products has introduced new ... for use with CRM, neurostimulation, vascular, and related devices. , Anomet Medical ... requirements, performance, and cost criteria; especially where solid wire is limited. Typical configurations ...
(Date:7/31/2020)... ... 29, 2020 , ... The SDX® Respiratory Gating System ... has reached its 20th anniversary of worldwide use. Introduced in the US over ... including University of Pennsylvania, University of Michigan, University of Maryland, University of California ...
Breaking Biology Technology: